DCF Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

DCF Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$312K	–	103
2025 Q4	$312K	Sell	10,000 -47,500	-83%	-$1.17M	0.08%	86
2025 Q3	$1.16M	Buy	57,500 +50,000	+667%	+$878K	0.37%	61
2025 Q2	$126K	Hold	7,500	–	–	0.06%	79
2025 Q1	$115K	Sell	7,500 -7,500	-50%	-$134K	0.06%	79
2024 Q4	$331K	Sell	15,000 -18,500	-55%	-$337K	0.16%	77
2024 Q3	$604K	Buy	33,500 +18,500	+123%	+$324K	0.24%	66
2024 Q2	$244K	Sell	15,000 -7,500	-33%	-$116K	0.13%	82
2024 Q1	$317K	Buy	+22,500	New	+$284K	0.16%	70

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCF Advisers's TEVA Position: Q1 2026 in Review

DCF Advisers reduced its Teva Pharmaceuticals (TEVA) stake by 22% in Q1 2026, selling an estimated $2.73M and leaving 300,000 shares worth $9.04M. The position accounts for 2.41% of the portfolio, ranked #8.

DCF Advisers first reported a position in TEVA in Q2 2023 and has held it in 12 quarters since. The position peaked at $12M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

DCF Advisers held 300,000 shares of Teva Pharmaceuticals worth $9.04M as of Q1 2026.
DCF Advisers sold 85,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $2.73M.
Teva Pharmaceuticals made up 2.41% of DCF Advisers's portfolio in Q1 2026, its #8 holding.
DCF Advisers first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
DCF Advisers's Teva Pharmaceuticals position peaked at $12M in Q4 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.